N
35.46
1.18 (3.44%)
| 前收盘价格 | 34.28 |
| 收盘价格 | 33.41 |
| 成交量 | 673,684 |
| 平均成交量 (3个月) | 804,450 |
| 市值 | 4,077,028,352 |
| 价格/销量 (P/S) | 180.30 |
| 股市价格/股市净资产 (P/B) | 5.76 |
| 52周波幅 | |
| 利润日期 | 7 May 2026 |
| 营业利益率 (TTM) | -2,314.47% |
| 稀释每股收益 (EPS TTM) | -1.84 |
| 季度收入增长率 (YOY) | 112.60% |
| 总债务/股东权益 (D/E MRQ) | 0.05% |
| 流动比率 (MRQ) | 19.98 |
| 营业现金流 (OCF TTM) | -140.43 M |
| 杠杆自由现金流 (LFCF TTM) | -99.00 M |
| 资产报酬率 (ROA TTM) | -18.15% |
| 股东权益报酬率 (ROE TTM) | -31.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | NewAmsterdam Pharma Company N.V | 看跌 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.38 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 0.39% |
| 机构持股比例 | 111.32% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 50.00 (Stifel, 41.00%) | 购买 |
| 中 | 47.50 (33.95%) | |
| 低 | 45.00 (Guggenheim, 26.90%) | 购买 |
| 平均值 | 47.50 (33.95%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 34.64 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 19 Feb 2026 | 45.00 (26.90%) | 购买 | 34.63 |
| Needham | 18 Feb 2026 | 48.00 (35.36%) | 购买 | 35.76 |
| RBC Capital | 21 Jan 2026 | 47.00 (32.54%) | 购买 | 33.94 |
| Stifel | 16 Dec 2025 | 50.00 (41.00%) | 购买 | 34.22 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合